Cargando…

Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging

Objective: The aim of this retrospective cohort study is to evaluate the concordance between the preoperative MRI and histology data with the final histopathological examination. Method: This is a retrospective observational study of 183 patients operated for endometrioid cancer between January 2009...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouche, Caroline, Gomes David, Manuel, Salleron, Julia, Rauch, Philippe, Leufflen, Léa, Buhler, Julie, Marchal, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761973/
https://www.ncbi.nlm.nih.gov/pubmed/33291658
http://dx.doi.org/10.3390/diagnostics10121045
_version_ 1783627694259306496
author Bouche, Caroline
Gomes David, Manuel
Salleron, Julia
Rauch, Philippe
Leufflen, Léa
Buhler, Julie
Marchal, Frédéric
author_facet Bouche, Caroline
Gomes David, Manuel
Salleron, Julia
Rauch, Philippe
Leufflen, Léa
Buhler, Julie
Marchal, Frédéric
author_sort Bouche, Caroline
collection PubMed
description Objective: The aim of this retrospective cohort study is to evaluate the concordance between the preoperative MRI and histology data with the final histopathological examination. Method: This is a retrospective observational study of 183 patients operated for endometrioid cancer between January 2009 and December 2019 in the surgical oncology department of the Lorraine Cancer Institute (ICL) in Vandœuvre-lès-Nancy. The patients included are all women operated on for endometrioid-type endometrial cancer over this period. The exclusion criteria are patients for whom the pre-therapy check-up does not include pelvic MRI and those who have not had first-line surgery. The final anatomopathological results were compared with preoperative imaging data and with endometrial biopsy data. Results: For the myometrial infiltration, the sensitivity of MRI was of 37% and the specificity of 54%. To detect nodal metastases, the sensitivity of MRI was of 21% and the specificity of 93%. We observed an under estimation of the FIGO classification (p = 0.001) with the MRI in 42.7% of cases (n = 76) and an overestimation in 24.2% of cases (n = 43). There was a concordance in 33.1% of cases (n = 59). We had a poor agreement between the MRI and final histopathological examination with an adjusted kappa (κ) of 0.12 [95% IC (0.02; 0.24)]. There was a moderate concordance on the grade between the pretherapeutic biopsy and the final histopathological examination on excised tissue with an adjusted kappa of 0.52 [95% IC 0.42–0.62)]. Endometrial biopsy underestimated the tumor grade in 28.9% of cases (n = 50) (p < 0.001), overestimated the tumor grade in 6.9% of cases (n = 12) and we observed a concordance in 64.2% of cases (n = 111). Conclusion: The pre-operative assessment of endometrial cancer is inconsistent with the results obtained on final histopathological examination. A study with a systematic review should be done to assess the performance of MRI, only in expert centers, in order to consider a a specific care management for endometrial cancer patients: patients who have had an MRI in an outpatient center should have their imaging systematically reviewed, with the possibility of a new examination in case of incomplete sequences, by expert radiologists, and discussed in multidisciplinary concertation meeting in expert centers, before any therapeutic decision. The sentinel node biopsy must be used for low and intermediate risk endometrial cancer.
format Online
Article
Text
id pubmed-7761973
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77619732020-12-26 Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging Bouche, Caroline Gomes David, Manuel Salleron, Julia Rauch, Philippe Leufflen, Léa Buhler, Julie Marchal, Frédéric Diagnostics (Basel) Article Objective: The aim of this retrospective cohort study is to evaluate the concordance between the preoperative MRI and histology data with the final histopathological examination. Method: This is a retrospective observational study of 183 patients operated for endometrioid cancer between January 2009 and December 2019 in the surgical oncology department of the Lorraine Cancer Institute (ICL) in Vandœuvre-lès-Nancy. The patients included are all women operated on for endometrioid-type endometrial cancer over this period. The exclusion criteria are patients for whom the pre-therapy check-up does not include pelvic MRI and those who have not had first-line surgery. The final anatomopathological results were compared with preoperative imaging data and with endometrial biopsy data. Results: For the myometrial infiltration, the sensitivity of MRI was of 37% and the specificity of 54%. To detect nodal metastases, the sensitivity of MRI was of 21% and the specificity of 93%. We observed an under estimation of the FIGO classification (p = 0.001) with the MRI in 42.7% of cases (n = 76) and an overestimation in 24.2% of cases (n = 43). There was a concordance in 33.1% of cases (n = 59). We had a poor agreement between the MRI and final histopathological examination with an adjusted kappa (κ) of 0.12 [95% IC (0.02; 0.24)]. There was a moderate concordance on the grade between the pretherapeutic biopsy and the final histopathological examination on excised tissue with an adjusted kappa of 0.52 [95% IC 0.42–0.62)]. Endometrial biopsy underestimated the tumor grade in 28.9% of cases (n = 50) (p < 0.001), overestimated the tumor grade in 6.9% of cases (n = 12) and we observed a concordance in 64.2% of cases (n = 111). Conclusion: The pre-operative assessment of endometrial cancer is inconsistent with the results obtained on final histopathological examination. A study with a systematic review should be done to assess the performance of MRI, only in expert centers, in order to consider a a specific care management for endometrial cancer patients: patients who have had an MRI in an outpatient center should have their imaging systematically reviewed, with the possibility of a new examination in case of incomplete sequences, by expert radiologists, and discussed in multidisciplinary concertation meeting in expert centers, before any therapeutic decision. The sentinel node biopsy must be used for low and intermediate risk endometrial cancer. MDPI 2020-12-04 /pmc/articles/PMC7761973/ /pubmed/33291658 http://dx.doi.org/10.3390/diagnostics10121045 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bouche, Caroline
Gomes David, Manuel
Salleron, Julia
Rauch, Philippe
Leufflen, Léa
Buhler, Julie
Marchal, Frédéric
Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging
title Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging
title_full Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging
title_fullStr Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging
title_full_unstemmed Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging
title_short Evaluation of Pre-Therapeutic Assessment in Endometrial Cancer Staging
title_sort evaluation of pre-therapeutic assessment in endometrial cancer staging
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761973/
https://www.ncbi.nlm.nih.gov/pubmed/33291658
http://dx.doi.org/10.3390/diagnostics10121045
work_keys_str_mv AT bouchecaroline evaluationofpretherapeuticassessmentinendometrialcancerstaging
AT gomesdavidmanuel evaluationofpretherapeuticassessmentinendometrialcancerstaging
AT salleronjulia evaluationofpretherapeuticassessmentinendometrialcancerstaging
AT rauchphilippe evaluationofpretherapeuticassessmentinendometrialcancerstaging
AT leufflenlea evaluationofpretherapeuticassessmentinendometrialcancerstaging
AT buhlerjulie evaluationofpretherapeuticassessmentinendometrialcancerstaging
AT marchalfrederic evaluationofpretherapeuticassessmentinendometrialcancerstaging